TOP > 外国特許検索 > PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYDROCEPHALUS

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYDROCEPHALUS

外国特許コード F180009458
整理番号 (S2017-0064-N0)
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP038203
国際公開番号 WO 2018079493
国際出願日 平成29年10月23日(2017.10.23)
国際公開日 平成30年5月3日(2018.5.3)
優先権データ
  • 特願2016-208438 (2016.10.25) JP
発明の名称 (英語) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYDROCEPHALUS
発明の概要(英語) The purpose of the present invention is to provide a new pharmaceutical composition for prevention or treatment of hydrocephalus, and a diagnosis kit that does not place a heavy burden on a patient. Further, the purpose of the present invention is to provide a new method for prevention and treatment of hydrocephalus as well as a diagnosis method of hydrocephalus that reduces the burden on a patient. Provided are: a pharmaceutical composition for prevention or treatment of hydrocephalus, the composition containing a Tsukushi protein; a method for diagnosing hydrocephalus that includes the detection of amino acid substitution of a Tsukushi protein or a Tsukushi gene mutation which causes such amino acid substitution; and the like.
従来技術、競合技術の概要(英語) BACKGROUND ART
Hydrocephalus, excess cerebrospinal fluid from accumulating in the head is compressed in the brain disease, fatal in the case of a newborn in some cases. 'Idiopathic normal use of the head under pressure' annual national patient has been diagnosed with a person 13,000 is estimated, the acquired 'idiopathic normal use of the head under pressure' of the symptoms, headache or nerve compression blindness, memory disorders, such as a behavior abnormality, the abnormal state by observing the nerve. Treatment methods include, ventricular-abdominal and lumbar surgery shunt-shunt is operative abdominal cavity has been developed, the development of new therapies has been demanded.
Surgical interventions for the treatment of hydrocephalus as a method other than the, hepatocyte growth factor (HGF) in the brain ventricles (Patent Document 1) or is administered, bioavailability DFfolate a method of using a derivative or a salt thereof (Patent Document 2) and the like have been heretofore disclosed.
In addition, in Patent Document 3, small leucine-rich proteoglycans (SLRP) in the canal by administering decorin, the central nervous system tissue SLRP can be directly administered to, cerebral spinal fluid (CSF) are injected into the system described.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • OHTA Kunimasa
  • ITO Naofumi
  • Ahmad Shah Adil Ishtiyaq
国際特許分類(IPC)
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close